These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34331805)

  • 1. Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
    Roblin X; Nancey S; Paul S
    Aliment Pharmacol Ther; 2021 Aug; 54(4):538-539. PubMed ID: 34331805
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies.
    Demarzo MG; Bodini G; Giuliana E; Zentilin P; Giannini EG
    Aliment Pharmacol Ther; 2021 Aug; 54(4):536-537. PubMed ID: 34331789
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD? Authors' reply.
    Roblin X; Paul S
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1051. PubMed ID: 35362121
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply.
    Sethi S; Kumar A; Dias S; Blackwell J; Brookes MJ; Segal JP
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1455-1456. PubMed ID: 37243471
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Roblin X; Nancey S; Paul S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1319-1320. PubMed ID: 34029416
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
    Kokkotis G; Kitsou K; Bamias G
    Aliment Pharmacol Ther; 2022 May; 55(9):1235-1236. PubMed ID: 35429035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?
    Roblin X; Vérot C; Paul S; Duru G; Williet N; Boschetti G; Del Tedesco E; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Inflamm Bowel Dis; 2018 Aug; 24(9):2078-2085. PubMed ID: 29718216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
    Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
    Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
    Blesl A; Högenauer C; Borenich A; Berghold A; Wenzl H; Petritsch W
    Aliment Pharmacol Ther; 2021 Sep; 54(5):720-721. PubMed ID: 34379834
    [No Abstract]   [Full Text] [Related]  

  • 10. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis.
    Dhindsa BS; Dhaliwal A; Mashiana HS; Saghir SM; Sayles H; Mubder M; Ohning G; Eichele D
    Indian J Gastroenterol; 2020 Apr; 39(2):153-160. PubMed ID: 32468382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease.
    Thomas PWA; Chin PKL; Barclay ML
    Intern Med J; 2021 Mar; 51(3):341-347. PubMed ID: 32043746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
    Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J
    Aliment Pharmacol Ther; 2021 May; 53(9):1046-1047. PubMed ID: 33831234
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
    Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing anti-TNF treatments in inflammatory bowel disease.
    Ben-Horin S; Kopylov U; Chowers Y
    Autoimmun Rev; 2014 Jan; 13(1):24-30. PubMed ID: 23792214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
    Bar-Yoseph H; Pressman S; Blatt A; Gerassy Vainberg S; Maimon N; Starosvetsky E; Ungar B; Ben-Horin S; Shen-Orr SS; Chowers Y;
    Gastroenterology; 2019 Nov; 157(5):1338-1351.e8. PubMed ID: 31401142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
    de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
    J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-tumor necrosis factor therapy in Bulgarian pediatric patients with inflammatory bowel disease - an 8-year experience of a referral center.
    Shentova-Eneva RR; Kofinova DR; Baycheva MZ; Hadzhiyski PG; Naydenov HB; Yaneva PG; Lazarova EA
    Folia Med (Plovdiv); 2023 Aug; 65(4):605-611. PubMed ID: 37655379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.